

1 **Cellular Signalling Revised MS CLS-D-16-00264**

2  
3  
4  
5 3  
6  
7 4 **A novel regulatory relationship between RIPK4 and ELF3 in keratinocytes**  
8  
9

10 5  
11 6 Glen M. Scholz, Nur S. Sulaiman<sup>1</sup>, Sahar Al Baiiaty<sup>1</sup>, Mei Qi Kwa<sup>2</sup>, and Eric C. Reynolds  
12  
13  
14 7

15  
16 8 Oral Health Cooperative Research Centre, Melbourne Dental School, Bio21 Molecular  
17  
18 9 Science and Biotechnology Institute, University of Melbourne, Victoria 3010, Australia.  
19  
20  
21

22 10  
23  
24 11 <sup>1</sup> These authors made equal contributions.  
25

26 12 <sup>2</sup> Current address: Institute of Molecular and Cell Biology, A\*STAR, Singapore.  
27  
28  
29 13

30  
31 14 Running title: RIPK4 and ELF3 in keratinocytes  
32  
33  
34 15

35  
36 16 The abbreviations used are: ActD, actinomycin D; CHX, cycloheximide; ELF3, E74-like  
37  
38 17 factor 3; GRHL3, Grainyhead-like 3; IRF6, Interferon regulatory factor 6; IVL, involucrin;  
39  
40 18 OVOL1, Ovo-like zinc-finger 1; RIPK, Receptor-interacting protein kinase; SPRR, small  
41  
42 19 proline-rich protein; TGM, transglutaminase.  
43  
44  
45  
46 20  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

21 **Abstract**

22 Keratinocytes are central to the barrier functions of surface epithelia, such as the gingiva  
23 and epidermis. RIPK4 is a key regulator of keratinocyte differentiation; however, the  
24 signalling pathways in which it functions remain poorly defined. In this study, we identified a  
25 regulatory relationship between RIPK4 and ELF3, an ETS family transcription factor. RIPK4  
26 was shown to be important for the upregulation of ELF3 gene expression by the PKC agonist  
27 PMA in both oral and epidermal keratinocytes. RIPK4 promotes keratinocyte differentiation  
28 in part by phosphorylating and thereby activating the IRF6 transcription factor. Significantly,  
29 silencing of IRF6 inhibited the PMA-inducible expression of ELF3. A role for the GRHL3  
30 transcription factor, a downstream target gene of IRF6, in the regulation of ELF3 expression  
31 was similarly demonstrated. ELF3 has previously been shown to regulate the expression of  
32 SPPR1A and SPRR1B, small proline-rich proteins that contribute to the cornification of  
33 keratinocytes. Consistently, RIPK4 and IRF6 were shown to be required for the PMA-  
34 inducible expression of SPRR1A and SPRR1B. They were also shown to be important for the  
35 upregulation of TGM1, a transglutaminase that catalyses the cross-linking of proteins,  
36 including small proline-rich proteins, during keratinocyte cornification. RIPK4 was also  
37 shown to upregulate the expression of TGM2 independently of IRF6. Collectively, our  
38 findings position RIPK4 upstream of a hierarchal IRF6-GRHL3-ELF3 transcription factor  
39 pathway in keratinocytes, as well as provide insight into a potential role for RIPK4 in the  
40 regulation of keratinocyte cornification.

## 41 **1. Introduction**

42 The stratified squamous epithelia of the oral cavity, as well as other surface epithelia  
43 (e.g. epidermis), provide protection against mechanical and chemical damage, and biological  
44 insults [1, 2]. The epithelia, which are organised into layers of morphologically and  
45 biochemically distinct cells, are highly dynamic and maintained through tightly regulated  
46 keratinocyte proliferation and differentiation [2, 3]. Tissue renewal, in turn, is initiated by  
47 stem cell populations in the basal layer that undergo a limited number of cell divisions before  
48 initiating terminal differentiation as they migrate towards the superficial layers. Depending on  
49 anatomical location, keratinocytes may also become enucleated, flattened, and cornified [2-4].

50 Cornification greatly strengthens the barrier functions of keratinocytes. During the final  
51 stages of keratinocyte terminal differentiation, the nucleus and its DNA are degraded and  
52 keratin filaments are aggregated into tight bundles by filaggrin to promote the collapsing of  
53 the cell into a flattened shape [2, 4]. Concomitantly, the cornified envelope is assembled just  
54 under the cell membrane through the cross-linking of various proteins (e.g. involucrin,  
55 loricrin, and small proline-rich proteins) by calcium-dependent transglutaminases, for  
56 example, transglutaminase-1 (TGM1). Intracellular lipids from lamellar bodies are also  
57 deposited in the cell membrane, where they become covalently attached to the cornified  
58 envelope as well as extruded from the cell to form intercellular lamellae. Collectively, this  
59 results in the replacement of the keratinocyte cell membrane with an insoluble structure that  
60 protects the underlying epithelial tissues [2, 4]. Keratinocytes also play active roles in  
61 epithelial homeostasis and host defence by producing cytokines that promote inflammation  
62 and wound healing in response to injury and infection [5].

63 Receptor-interacting protein kinase 4 (RIPK4) is an important regulator of keratinocyte  
64 differentiation [6]. For instance, the epidermis of Ripk4-deficient mice is disorganised and  
65 expanded, and the outermost cornified layers are absent, resulting in defective barrier function

66 [6, 7]. Mutations in RIPK4 cause Bartsocas-Papas syndrome [8, 9], a congenital syndrome  
67 that is characterised by severe oral and epidermal abnormalities. At the molecular level,  
68 RIPK4 can activate NF- $\kappa$ B [10-13], a critical regulator of epithelial tissue homeostasis [14].  
69 Significantly, RIPK4 can directly activate Interferon regulatory factor 6 (IRF6) [12]. IRF6 is  
70 an important transcriptional regulator of keratinocyte differentiation and promotes the switch  
71 from proliferation to differentiation [15, 16]. IRF6 regulates keratinocyte differentiation in  
72 part by inducing the expression of the transcription factors Grainyhead-like 3 (GRHL3) and  
73 Ovo-like zinc-finger 1 (OVOL1) [12, 17, 18]. Similar to Ripk4-deficient mice, the spinous  
74 layer in the epidermis of Irf6-deficient mice is expanded, and the granular and cornified layers  
75 appear to be absent [15]. We recently established that RIPK4 also regulates the expression of  
76 proinflammatory cytokines by keratinocytes through its activation of IRF6 [19]. Thus, RIPK4  
77 appears to function as a key regulatory nodal point in the maintenance of epithelia  
78 homeostasis.

79 To understand further the role of RIPK4 in keratinocytes, we sought to identify  
80 additional target genes of RIPK4 signalling. We show here that RIPK4 signalling regulates  
81 the expression of the ETS family transcription factor E74-like factor 3 (ELF3) in human  
82 keratinocytes. Specifically, our data suggest that RIPK4 promotes ELF3 gene expression via  
83 the IRF6-mediated upregulation of GRHL3. Moreover, this RIPK4-regulated IRF6-GRHL3-  
84 ELF3 transcriptional network appears to control the expression of genes (e.g. SPRR1 and  
85 TGM1) that directly mediate keratinocyte cornification.

## 87 **2. Materials and Methods**

### 88 *2.1 Reagents*

89 Keratinocyte serum-free medium and supplements (human EGF and bovine pituitary extract)  
90 (Cat. no. 37010022), GlutaMax-1 (Cat. no. 35050061), Opti-MEM I reduced serum medium

91 (Cat. no. 31985062), Lipofectamine RNAiMAX transfection reagent (Cat. no. 13778150), and  
92 the Silencer Select RIPK4 siRNA (Cat. no. 4390824, siRNA ID: s28865) and GRHL3 siRNA  
93 (Cat. no. 4392420, siRNA ID: s33754) were from Life Technologies. KGM-Gold BulletKit  
94 keratinocyte growth medium (Cat. no. 00192152) and ReagentPack (Cat. no. CC-5034) were  
95 purchased from Lonza. The ON-TARGETplus IRF6 siRNA (Cat. no. J-012227-05) was from  
96 GE Healthcare. Phorbol 12-myristate 13-acetate (Cat. no. P8139), actinomycin D (Cat. no.  
97 A9415), cycloheximide (Cat. no. C7698), and dimethylsulphoxide (Cat. no. D8418) were  
98 from Sigma-Aldrich.

## 100 2.2 Cell culture

101 Human OKF6/TERT-2 oral keratinocytes were cultured in keratinocyte serum-free medium  
102 supplemented with 0.4 ng/ml human EGF, 25 µg/ml bovine pituitary extract, 0.4 mM CaCl<sub>2</sub>,  
103 and 2 mM GlutaMax-1. Normal human epidermal keratinocytes were obtained from Lonza  
104 (Cat. no. 192627) and cultured in KGM-Gold medium according to the protocol provided by  
105 the supplier. All cells were maintained at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>.

## 107 2.3 Stimulation of keratinocytes with phorbol 12-myristate 13-acetate

108 OKF6/TERT-2 cells and normal human epidermal keratinocytes were allowed to adhere  
109 overnight. Thereafter, the cells were stimulated with 100 ng/ml phorbol 12-myristate 13-  
110 acetate (PMA) in dimethylsulfoxide (DMSO) for the times indicated in the figure legends.  
111 Time-matched, control cells were treated with 0.1% DMSO.

## 113 2.4 Inhibition of RNA transcription and protein synthesis

114 RNA transcription was inhibited by pretreating OKF6/TERT-2 cells with 1 µg/ml  
115 actinomycin D for 30 min prior to stimulation with PMA for 6 h. Protein synthesis was

116 inhibited by pretreating cells with 20 µg/ml cycloheximide for 30 min prior to stimulation  
117 with PMA for 6 h. Time-matched, control cells were treated with 0.1% DMSO or 0.1%  
118 ethanol, respectively.

119

## 120 2.5 RNA interference-mediated gene silencing

121 A reverse-transfection protocol was used for siRNA transfection of OKF6/TERT-2 cells and  
122 normal human epidermal keratinocytes. Briefly, the siRNA were diluted to 120 nM with 100  
123 µl Opti-MEM I reduced serum medium, mixed with 100 µl Opti-MEM I reduced serum  
124 medium containing 1 µl Lipofectamine RNAiMAX (Life Technologies), and incubated at  
125 room-temperature for 15-20 min. OKF6/TERT-2 cells and normal human epidermal  
126 keratinocytes ( $2 \times 10^5$  cells in 1 ml medium) were seeded into 12-well plates and incubated  
127 with the siRNA transfection cocktail overnight. Thereafter, the medium was replaced and the  
128 cells stimulated with PMA 48 h (OKF6/TERT-2 cells) or 72 h (normal human epidermal  
129 keratinocytes) post-transfection.

130

## 131 2.6 RNA purification and reverse transcription

132 Total RNA was purified using the ReliaPrep RNA Cell miniprep system (Promega, Cat. no.  
133 Z6012), which includes an on-column DNase-treatment step. RNA was reverse transcribed  
134 into cDNA using random primers and GoScript Reverse Transcriptase (Promega, Cat. no.  
135 A6110) according to the manufacturer's instructions. Briefly, 500 ng RNA was incubated in  
136 20 µl of reaction buffer supplemented with MgCl<sub>2</sub>, PCR nucleotide mix, RNasin ribonuclease  
137 inhibitor, 500 ng random primers, and 1 µl GoScript Reverse Transcriptase, for: 5 min at  
138 25°C, 60 min at 42°C, and 15 min at 75°C. The cDNA was typically diluted 1:4 with water  
139 prior to analysis by real-time PCR.

140

141 2.7 *Gene expression profiling*

1  
2 142 Two micrograms of RNA was reverse transcribed as described above. The cDNA (100 ng/μl)  
3  
4  
5 143 was mixed with TaqMan OpenArray Real-Time master mix (Life Technologies, Cat no.  
6  
7 144 4462164), and then loaded onto an OpenArray Human Inflammation plate (Life  
8  
9  
10 145 Technologies, Cat. no. 4475389) using an OpenArray AccuFill System. PCR was performed  
11  
12 146 on a QuantStudio 12K Flex Real-Time PCR System. The data were normalised against  
13  
14 147 hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene expression using Expression  
15  
16  
17 148 Suite Software (version 1.0.1).

149  
20  
21  
22 150 2.8 *Quantitative real-time PCR*

23  
24 151 Quantitative real-time PCR (qPCR) was performed in triplicate using GoTaq Probe qPCR  
25  
26 152 Master Mix (Promega, Cat. no. A6102) and pre-developed TaqMan assays (Life  
27  
28  
29 153 Technologies) for the following genes: ELF3 (Assay ID: Hs00963881\_m1), GRHL3 (Assay  
30  
31 154 ID: Hs00297962\_m1), IRF6 (Assay ID: Hs00196213\_m1), IVL (Assay ID:  
32  
33  
34 155 Hs00902520\_m1), OVOL1 (Assay ID: Hs00190060\_m1), RIPK4 (Assay ID:  
35  
36 156 Hs01062501\_m1), SPRR1A (Assay ID: Hs00954595\_s1), SPRR1B (Assay ID:  
37  
38  
39 157 Hs00824893\_m1), TGM1 (Assay ID: Hs00165929\_m1), TGM2 (Assay ID:  
40  
41 158 Hs00190278\_m1), and TGM3 (Assay ID: Hs00162752\_m1). PCR was performed on a  
42  
43  
44 159 QuantStudio 7 Flex Real-Time PCR System, and the data was normalised against HPRT (Life  
45  
46 160 Technologies, Cat. no. 4326321E) or TBP (Life Technologies, Cat. no. 4326322E) gene  
47  
48  
49 161 expression.

50  
51 162  
52  
53 163 2.9 *Statistical analysis*

54  
55  
56 164 Data combined from three or more independent biological replicates are presented as the  
57  
58 165 mean ± SEM. Statistical analysis was performed using GraphPad Prism 6 (GraphPad  
59  
60  
61  
62  
63  
64  
65

166 Software). Differences between two groups were evaluated using the Student's *t* test. For  
167 multiple comparisons, statistical analysis was performed using a one-way analysis of variance  
168 (ANOVA). A *p* value <0.05 was considered to be statistically significant.

### 170 **3. Results**

#### 171 *3.1 RIPK4 regulates ELF3 gene expression in human keratinocytes*

172 In addition to regulating the PKC-mediated differentiation of keratinocytes [12], RIPK4  
173 also regulates their expression of proinflammatory cytokines [19]. To understand further the  
174 function of RIPK4 in keratinocytes, we sought to identify additional target genes of RIPK4  
175 signalling. To that end, OKF6/TERT-2 human oral keratinocytes (hereafter referred to as  
176 OKF6 cells) were transfected with a RIPK4 siRNA (**Fig. 1A**), and subsequently stimulated  
177 with the PKC agonist phorbol 12-myristate 13-acetate (PMA). Genes that were dependent on  
178 RIPK4 for their PMA-inducible expression were identified using the OpenArray Human  
179 Inflammation panel, and specific genes then validated by real-time PCR (qPCR). In addition  
180 to inflammatory cytokines, including some we had recently identified (e.g. CCL5) [19], ELF3  
181 was identified as a PMA-inducible, RIPK4-dependent gene (**Fig. 1B**). ELF3 is an epithelium-  
182 specific ETS family transcription factor, and its expression is upregulated during calcium-  
183 induced epidermal keratinocyte differentiation [20, 21]. Basal ELF3 gene expression in OKF6  
184 cells was also found to be RIPK4-dependent (**Fig. 1B**). Given that RIPK4 partly regulates  
185 downstream gene expression by activating IRF6 [12], we investigated whether IRF6 was  
186 important for ELF3 gene expression. The transfection of OKF6 cells with an IRF6 siRNA,  
187 which reduced IRF6 expression by >80% (**Fig. 1C**), strongly inhibited the PMA-inducible  
188 expression of ELF3 (**Fig. 1D**). The silencing of RIPK4 and IRF6 also inhibited the stimulation  
189 of ELF3 gene expression by PMA in normal human epidermal keratinocytes (**Fig. 1E-F**).



190 Collectively, these data suggest that RIPK4 regulates ELF3 gene expression in keratinocytes  
1  
2 by activating IRF6.  
3

4  
5 192

### 6 7 193 *3.2 ELF3 gene expression is regulated downstream of GRHL3 in keratinocytes*

8  
9 194 A putative IRF6-response element has recently been described for several IRF6-regulated  
10  
11 genes, including GRHL3 [17, 18]. However, we were unable to identify potential binding  
12 195 sites for IRF6 in the ELF3 gene (data not shown). IRF6 promotes PKC-mediated keratinocyte  
13  
14 196 differentiation in part by upregulating the expression of GRHL3 [12]. Therefore, we  
15  
16 197 compared the kinetics of the PMA-inducible expression of ELF3 and GRHL3 in OKF6 cells.  
17  
18 198 Significantly, ELF3 gene expression (**Fig. 2A**) was induced more slowly than GRHL3 (**Fig.**  
19  
20 199 **2B**). OKF6 cells were also pretreated with actinomycin D (ActD) prior to PMA stimulation to  
21  
22 200 demonstrate that the increase in ELF3 mRNA levels was due to transcription and not mRNA  
23  
24 201 stabilisation (**Fig. 2C**). Given these findings, we investigated if GRHL3 was important for  
25  
26 202 ELF3 gene expression. Indeed, the silencing of GRHL3 in OKF6 cells inhibited the PMA-  
27  
28 203 inducible expression of ELF3 (**Fig. 2D**). The PMA-inducible expression of involucrin (IVL),  
29  
30 204 an early marker of keratinocyte terminal differentiation, and a component of the cornified  
31  
32 205 envelope [2, 4], was also inhibited (**Fig. 2E**). As expected, the PMA-inducible expression of  
33  
34 206 OVOL1, a direct IRF6 target gene [17], was unaffected by the silencing of GRHL3 (**Fig. 2F**).  
35  
36 207 Taken together, these results suggest that GRHL3 functions downstream of RIPK4 and IRF6  
37  
38 208 to regulate ELF3 gene expression in keratinocytes.  
39  
40 209  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 210

### 52 53 211 *3.3 Inhibition of protein synthesis upregulates ELF3 gene expression in keratinocytes*

54 212 To investigate further the mechanism underlying the PMA-inducible expression of ELF3 in  
55  
56 213 keratinocytes, the effect of the protein synthesis inhibitor cycloheximide (CHX) on ELF3  
57  
58 214 gene expression was investigated. As shown in **Fig. 3A**, CHX did not inhibit the PMA-  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
215 inducible expression of ELF3. However, CHX treatment alone resulted in a largely  
216 comparable increase in ELF3 mRNA levels (**Fig. 3A**). OKF6 cells were also treated with  
217 CHX and ActD concurrently to confirm that the increase in ELF3 mRNA was transcription-  
218 dependent (**Fig. 3A**). In view of these findings, the effects of CHX on basal and PMA-  
219 inducible IRF6 and GRHL3 gene expression were also investigated. As for ELF3, IRF6 and  
220 GRHL3 mRNA levels were significantly increased in CHX-treated cells (**Fig. 3B-C**).  
221 Furthermore, the magnitudes of the stimulatory effects of CHX on IRF6 and GRHL3 mRNA  
222 levels were comparable to those exerted by PMA (**Fig. 3B-C**). A further small increase in  
223 IRF6 mRNA levels was apparent when the cells were treated with PMA and CHX  
224 concurrently (**Fig. 3B**). Notably, concurrent treatment with PMA and CHX synergistically  
225 increased GRHL3 mRNA levels (**Fig. 3C**). RIPK4 mRNA levels were also upregulated in  
226 response to CHX treatment (**Fig. 3D**). These data suggest that, in addition to positive  
227 regulation, the expression of ELF3, IRF6, GRHL3, and RIPK4 in oral keratinocytes (e.g.  
228 OKF6 cells) may also be negatively regulated by transcriptional repressor proteins.

### 36 230 *3.4 RIPK4 regulates SPRR1 gene expression in keratinocytes*

37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
231 ELF3 has previously been shown to regulate the expression of small proline-rich proteins  
232 (SPRRs) [21-23], which are important components of the cornified envelope of terminally  
233 differentiated keratinocytes [2, 4]. For example, SPRR1 is a major component of the cell  
234 envelope of human oral keratinocytes [24]. Having established that RIPK4 regulates ELF3  
235 gene expression (**Fig. 1**), we therefore wanted to determine the importance of RIPK4 for  
236 SPRR1 gene expression. The stimulation of OKF6 cells with PMA resulted in the  
237 upregulation of SPRR1A and SPRR1B gene expression, and this was inhibited by the  
238 silencing of RIPK4 (**Fig. 4A-B**). RIPK4 was shown to also be important for the PMA-  
239 inducible expression of SPRR1A and SPRR1B in epidermal keratinocytes (**Fig. 4C-D**).

240 Similar to Ripk4-deficient mice, the cornified layers are also absent from the epidermis of  
241 Irf6-deficient mice [15]. Significantly, the PMA-inducible expression of SPRR1A and  
242 SPRR1B in OKF6 cells were shown to be IRF6-dependent (**Fig. 4E-F**). Interestingly, GRHL3  
243 was important for the upregulation of SPRR1A gene expression (**Fig. 4G**), whereas the PMA-  
244 inducible expression of SPRR1B was GRHL3-independent (**Fig. 4H**). The importance of the  
245 upregulation of ELF3 expression by PMA for subsequent SPRR1 gene induction was  
246 examined further by pretreating OKF6 cells with CHX. Consistently, the PMA-inducible  
247 expression of SPRR1A and SPRR1B were inhibited by CHX (**Fig. 4I-J**). In contrast to ELF3  
248 basal gene expression (**Fig. 3A**), CHX did not increase the basal gene expression levels of  
249 either SPRR1A (**Fig. 4I**) or SPRR1B (**Fig. 4J**). Taken together, these results are consistent  
250 with RIPK4 regulating SPRR1A and SPRR1B expression in keratinocytes through the IRF6-  
251 dependent induction of ELF3 gene expression.

### 3.5 *RIPK4 regulates TGM1 expression in keratinocytes*

254 The cross-linking of SPRRs to other proteins (e.g. loricrin) by transglutaminases (e.g. TGM1  
255 and TGM3) increases the strength and flexibility of the cornified envelope [2, 4]. Therefore,  
256 the importance of RIPK4 for the expression of TGM1 and TGM3 in keratinocytes was  
257 investigated. The stimulation of OKF6 cells with PMA resulted in the RIPK4-dependent  
258 upregulation of TGM1 gene expression (**Fig. 5A**). The PMA-inducible expression of TGM1  
259 in epidermal keratinocytes was also RIPK4-dependent (**Fig. 5B**). Similarly, the PMA-  
260 inducible expression of TGM1 in OKF6 cells was also inhibited by the silencing of IRF6  
261 (**Fig. 5C**) and GRHL3 (**Fig. 5D**). Given that the data presented in **Fig. 3** suggested that ELF3  
262 basal gene expression in OKF6 cells is partly regulated via transcriptional repression, the  
263 effect of CHX on TGM1 gene expression was determined. CHX did not increase TGM1  
264 mRNA levels in OKF6 cells (**Fig. 5E**), thereby distinguishing the mechanisms regulating

265 TGM1 and ELF3 basal gene expression in OKF6 cells. In contrast to TGM1, TGM3 gene  
266 expression in OKF6 cells was not upregulated by PMA (data not shown). These data suggest  
267 that TGM1 gene expression in PMA-treated keratinocytes is controlled by a RIPK4-IRF6-  
268 GRHL3 regulatory network.

269

### 3.6 *RIPK4 regulates TGM2 gene expression in keratinocytes independently of IRF6*

271 In contrast to TGM1 and TGM3, TGM2 is ubiquitously expressed and does not appear to play  
272 a role in keratinocyte cornification [25]. However, extracellular TGM2 can bind and cross-  
273 link extracellular matrix (ECM) components, which may help stabilise ECM-cell interactions  
274 [25]. Therefore, we investigated whether RIPK4 can regulate TGM2 gene expression. As  
275 shown in **Fig. 6A**, TGM2 mRNA levels in OKF6 cells were increased in response to PMA  
276 stimulation; moreover, the PMA-inducible expression of TGM2 was RIPK4-dependent (**Fig.**  
277 **6A**). On the other hand, neither IRF6 (**Fig. 6B**) nor GRHL3 (**Fig. 6C**) were required for the  
278 stimulation of TGM2 gene expression by PMA. Similar to TGM1 (**Fig. 5D**), the PMA-  
279 inducible expression of TGM2 was inhibited by CHX (**Fig. 6D**). These data suggest that  
280 RIPK4 functions independently of IRF6 and GRHL3 to regulate TGM2 gene expression in  
281 keratinocytes.

282

## 4. Discussion

284 Keratinocyte differentiation is central to maintaining the barrier functions of surface  
285 epithelia. Depending on anatomical location (e.g. gingiva and epidermis), keratinocytes may  
286 also become cornified, which increases their strength and hence barrier functions [2-4].  
287 Underpinning cornification are transcriptional networks which regulate the expression of  
288 structural proteins and enzymes that mediate the formation of the cornified envelope. Herein,  
289 we have established a role for RIPK4 in regulating an IRF6-GRHL3-ELF3 transcriptional

290 network that promotes the expression of small proline-rich proteins (e.g. SPRR1A) and  
291 transglutaminase-1 (TGM1) in keratinocytes. This would potentially position RIPK4 as an  
292 important regulator of keratinocyte cornification.

293 ELF3 was identified as a downstream target gene of RIPK4 signalling in OKF6 cells  
294 (e.g. oral keratinocytes) and epidermal keratinocytes. ELF3 is an epithelium-specific member  
295 of the ETS family of transcription factors [20, 21], and has previously been demonstrated to  
296 be important for enterocyte differentiation [26]. RIPK4 promotes keratinocyte differentiation  
297 in part by phosphorylating and activating IRF6, which, in turn, induces the expression of  
298 additional transcriptional regulators (e.g. GRHL3) [12]. Our finding that the silencing of IRF6  
299 inhibited the PMA-inducible expression of ELF3 therefore suggests that RIPK4 regulates  
300 ELF3 gene expression in keratinocytes, at least in part, by activating IRF6. The ELF3 gene  
301 does not appear to contain proximal IRF6 binding sites, and thus IRF6 likely regulates ELF3  
302 gene expression indirectly, for example, by regulating the expression of an intermediary  
303 transcription factor.

304 In this regard, GRHL3 was demonstrated to be important for ELF3 gene expression in  
305 keratinocytes. GRHL3 has been shown to regulate epidermal keratinocyte differentiation by  
306 recruiting the Trithorax complex to the promoters of epidermal differentiation genes (e.g.  
307 involucrin) [27]. The upregulation of GRHL3 expression in OKF6 cells by PMA largely  
308 preceded that of ELF3, and GRHL3 was demonstrated to be important for the PMA-inducible  
309 expression of ELF3. ELF3 was recently reported to be a direct target gene of GRHL3 in  
310 epidermal keratinocytes [28], and therefore GRHL3 likely functions downstream of RIPK4  
311 and IRF6 to mediate ELF3 gene expression. Interestingly, ELF3 was suggested to function  
312 upstream of GRHL3 in urothelial cells [29]. Additional studies will be required to fully  
313 understand the functional relationship between GRHL3 and ELF3 in regulating epithelial cell  
314 differentiation.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

315 Notably, inhibition of protein synthesis in OKF6 cells with cycloheximide resulted in  
316 transcription-dependent increases in IRF6, GRHL3, and ELF3 mRNA levels. This suggests  
317 that their expression in oral keratinocytes may also be regulated by transcriptional repressors.  
318 ZEB1, which is a key mediator of epithelial-mesenchymal transition [30], has been reported  
319 to repress IRF6 gene expression in mammary epithelial cells (e.g. MDA-MB-231 cells) [31].  
320 However, whether ZEB1, or other repressors (e.g. SNAIL proteins), can regulate keratinocyte  
321 differentiation by suppressing IRF6, GRHL3, and ELF3 gene transcription is yet to be  
322 established.

323 The slower induction of ELF3 gene expression by PMA in OKF6 cells is consistent  
324 with ELF3 potentially playing a role during the later stages of oral keratinocyte  
325 differentiation; indeed, ELF3 has been shown to be most highly expressed in the most  
326 differentiated layers of the epidermis [32]. Importantly, ELF3 can regulate the expression of  
327 small proline-rich proteins (SPRRs) [21-23]. The cross-linking of SPRRs to other structural  
328 proteins (e.g. loricrin) increases the strength of the cornified envelope, while their relatively  
329 limited organised structure likely increases envelope elasticity [2, 4]. Consistently, we found  
330 that RIPK4 was important for the upregulation of SPRR1 gene expression in PMA-treated  
331 keratinocytes (e.g. OKF6 cells and epidermal keratinocytes). IRF6 and GRHL3 were also  
332 shown to be important for the upregulation of SPRR1 gene expression. Accordingly, RIPK4  
333 likely regulates SPRR1 gene expression, at least in part, through its activation of an IRF6-  
334 GRHL3-ELF3 transcriptional network.

335 The cross-linking of SPRRs, structural proteins (e.g. involucrin and loricrin), and lipids  
336 into the cornified envelope is catalysed by transglutaminases [25]. TGM1 in particular has  
337 been shown to be essential for the formation of the cornified envelope and epidermal barrier  
338 function [33]. In line with an earlier report demonstrating the direct regulation of TGM1  
339 transcription by GRHL3 in epidermal keratinocytes [27], GRHL3 was shown here to be

340 important for the upregulation of TGM1 gene expression in oral keratinocytes (e.g. OKF6  
341 cells). RIPK4 and IRF6 were additionally shown to be important for the upregulation of  
342 TGM1 expression. Consequently, the ability of RIPK4 to activate the IRF6-GRHL3 pathway  
343 [12], and thereby induce TGM1 expression, potentially positions RIPK4 as a key regulator of  
344 keratinocyte cornification (**Fig. 7**).

345 RIPK4 was found to also be important for the upregulation of TGM2 gene expression in  
346 PMA-treated OKF6 cells. In contrast to its regulation of TGM1, RIPK4 regulated TGM2  
347 expression independently of both IRF6 and GRHL3. TGM2 gene expression has previously  
348 been shown to be regulated by NF- $\kappa$ B [34, 35], and thus RIPK4 likely regulates TGM2 gene  
349 expression in keratinocytes via its ability to activate NF- $\kappa$ B [10-12]. Although TGM2 does  
350 not appear to play a role in the formation of the cornified envelope, its cross-linking of  
351 extracellular matrix (ECM) components may nonetheless contribute to epithelial barrier  
352 function by decreasing ECM degradation as well as stabilising ECM-cell interactions [25].

353 Interestingly, RIPK4 has been found to be mutated in head and neck squamous cell  
354 carcinoma, including oral carcinoma [36], while the loss of ELF3 protein expression in oral  
355 squamous cell carcinoma was recently reported [37]. Therefore, the regulatory relationship  
356 between RIPK4 and ELF3 identified in this study may also be relevant to the development of  
357 squamous cell carcinoma.

358

## 359 **5. Conclusions**

360 In summary, we have identified and mechanistically defined a previously unrecognised  
361 regulatory relationship between RIPK4 and ELF3 in keratinocytes. Thus, RIPK4 might  
362 regulate the barrier functions of surface epithelia, at least in part, through its regulation of a  
363 hierarchal IRF6-GRHL3-ELF3 transcription factor pathway.

364

365 **Acknowledgements**

1  
2 366 This research was supported by the Australian Government, Department of Industry,  
3  
4  
5 367 Innovation and Science, and National Health and Medical Research Council Project Grant  
6  
7 368 628769.  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



369 **References**

- 1  
2  
3 370 [1] K.C. Madison, Barrier function of the skin: "la raison d'etre" of the epidermis, *J. Invest.*  
4  
5 371 *Dermatol.* 121 (2003) 231-241.  
6  
7 372 [2] R.B. Presland, B.A. Dale, Epithelial structural proteins of the skin and oral cavity:  
8  
9  
10 373 function in health and disease, *Crit. Rev. Oral Biol. Medicine* 11 (2000) 383-408.  
11  
12 374 [3] G. Donati, F.M. Watt, Stem cell heterogeneity and plasticity in epithelia, *Cell Stem Cell*  
13  
14  
15 375 16 (2015) 465-476.  
16  
17 376 [4] E. Candi, R. Schmidt, G. Melino, The cornified envelope: a model of cell death in the  
18  
19  
20 377 skin, *Nat. Rev. Mol. Cell Biol.* 6 (2005) 328-340.  
21  
22 378 [5] M. Pasparakis, I. Haase, F.O. Nestle, Mechanisms regulating skin immunity and  
23  
24  
25 379 inflammation, *Nat. Rev. Immunol.* 14 (2014) 289-301.  
26  
27 380 [6] P. Holland, C. Willis, S. Kanaly, M. Glaccum, A. Warren, K. Charrier, J. Murison, J.  
28  
29  
30 381 Derry, G. Virca, T. Bird, J. Peschon, RIP4 is an ankyrin repeat-containing kinase  
31  
32 382 essential for keratinocyte differentiation, *Curr. Biol.* 12 (2002) 1424-1428.  
33  
34 383 [7] P. De Groote, H.T. Tran, M. Fransen, G. Tanghe, C. Urwyler, B. De Craene, K. Leurs,  
35  
36  
37 384 B. Gilbert, G. Van Imschoot, R. De Rycke, C.J. Guerin, P. Holland, G. Berx, P.  
38  
39 385 Vandenameele, S. Lippens, K. Vleminckx, W. Declercq, A novel RIPK4-IRF6  
40  
41  
42 386 connection is required to prevent epithelial fusions characteristic for popliteal pterygium  
43  
44 387 syndromes, *Cell Death Differ.* 22 (2015) 1012-1024.  
45  
46 388 [8] E. Kalay, O. Sezgin, V. Chellappa, M. Mutlu, H. Morsy, H. Kayserili, E. Kreiger, A.  
47  
48  
49 389 Cansu, B. Toraman, E.M. Abdalla, Y. Aslan, S. Pillai, N.A. Akarsu, Mutations in  
50  
51  
52 390 RIPK4 cause the autosomal-recessive form of popliteal pterygium syndrome, *Am. J.*  
53  
54 391 *Hum. Genet.* 90 (2012) 76-85.  
55  
56 392 [9] K. Mitchell, J. O'Sullivan, C. Missero, E. Blair, R. Richardson, B. Anderson, D.  
57  
58  
59 393 Antonini, J.C. Murray, A.L. Shanske, B.C. Schutte, R.A. Romano, S. Sinha, S.S.

- 394 Bhaskar, G.C. Black, J. Dixon, M.J. Dixon, Exome sequence identifies RIPK4 as the  
1  
2 395 Bartsocas-Papas syndrome locus, *Am. J. Hum. Genet.* 90 (2012) 69-75.  
3  
4  
5 396 [10] E. Meylan, F. Martinon, M. Thome, M. Gschwendt, J. Tschopp, RIP4 (DIK/PKK), a  
6  
7 397 novel member of the RIP kinase family, activates NF-kappa B and is processed during  
8  
9 398 apoptosis, *EMBO Rep.* 3 (2002) 1201-1208.  
10  
11  
12 399 [11] A. Muto, J. Ruland, L.M. McAllister-Lucas, P.C. Lucas, S. Yamaoka, F.F. Chen, A.  
13  
14 400 Lin, T.W. Mak, G. Nunez, N. Inohara, Protein kinase C-associated kinase (PKK)  
15  
16 401 mediates Bcl10-independent NF-kappa B activation induced by phorbol ester, *J. Biol.*  
17  
18 402 *Chem.* 277 (2002) 31871-31876.  
19  
20  
21 403 [12] M.Q. Kwa, J. Huynh, J. Aw, L. Zhang, T. Nguyen, E.C. Reynolds, M.J. Sweet, J.A.  
22  
23 404 Hamilton, G.M. Scholz, Receptor-interacting protein kinase 4 and interferon regulatory  
24  
25 405 factor 6 function as a signaling axis to regulate keratinocyte differentiation, *J. Biol.*  
26  
27 406 *Chem.* 289 (2014) 31077-31087.  
28  
29  
30 407 [13] M.Q. Kwa, J. Huynh, E.C. Reynolds, J.A. Hamilton, G.M. Scholz, Disease-associated  
31  
32 408 mutations in IRF6 and RIPK4 dysregulate their signalling functions, *Cell. Signal.* 27  
33  
34 409 (2015) 1509-1516.  
35  
36  
37 410 [14] M. Pasparakis, Regulation of tissue homeostasis by NF-kappaB signalling: implications  
38  
39 411 for inflammatory diseases, *Nat. Rev. Immunol.* 9 (2009) 778-788.  
40  
41  
42 412 [15] C.R. Ingraham, A. Kinoshita, S. Kondo, B. Yang, S. Sajan, K.J. Trout, M.I. Malik, M.  
43  
44 413 Dunnwald, S.L. Goudy, M. Lovett, J.C. Murray, B.C. Schutte, Abnormal skin, limb and  
45  
46 414 craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6),  
47  
48  
49 415 *Nat Genet*  
50  
51  
52 416 *Nature Genetics* 38 (2006) 1335-1340.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- 417 [16] R.J. Richardson, J. Dixon, S. Malhotra, M.J. Hardman, L. Knowles, R.P. Boot-  
418 Handford, P. Shore, A. Whitmarsh, M.J. Dixon, Irf6 is a key determinant of the  
419 keratinocyte proliferation-differentiation switch, *Nat. Genet.* 38 (2006) 1329-1334.
- 420 [17] E. Botti, G. Spallone, F. Moretti, B. Marinari, V. Pinetti, S. Galanti, P.D. De Meo, F. De  
421 Nicola, F. Ganci, T. Castrignano, G. Pesole, S. Chimenti, L. Guerrini, M. Fanciulli, G.  
422 Blandino, M. Karin, A. Costanzo, Developmental factor IRF6 exhibits tumor suppressor  
423 activity in squamous cell carcinomas, *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011) 13710-  
424 13715.
- 425 [18] G. de la Garza, J.R. Schleiffarth, M. Dunnwald, A. Mankad, J.L. Weirather, G. Bonde,  
426 S. Butcher, T.A. Mansour, Y.A. Kousa, C.F. Fukazawa, D.W. Houston, J.R. Manak,  
427 B.C. Schutte, D.S. Wagner, R.A. Cornell, Interferon regulatory factor 6 promotes  
428 differentiation of the periderm by activating expression of Grainyhead-like 3, *J. Invest.*  
429 *Dermatol.* 133 (2013) 68-77.
- 430 [19] M.Q. Kwa, G.M. Scholz, E.C. Reynolds, RIPK4 activates an IRF6-mediated  
431 proinflammatory cytokine response in keratinocytes, *Cytokine* 83 (2016) 19-26.
- 432 [20] M.J. Tymms, A.Y. Ng, R.S. Thomas, B.C. Schutte, J. Zhou, H.J. Eyre, G.R. Sutherland,  
433 A. Seth, M. Rosenberg, T. Papas, C. Debouck, I. Kola, A novel epithelial-expressed  
434 ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization,  
435 human mapping to 1q32.2 and expression in tissues and cancer, *Oncogene* 15 (1997)  
436 2449-2462.
- 437 [21] P. Oettgen, R.M. Alani, M.A. Barcinski, L. Brown, Y. Akbarali, J. Boltax, C. Kunsch,  
438 K. Munger, T.A. Libermann, Isolation and characterization of a novel epithelium-  
439 specific transcription factor, ESE-1, a member of the ets family, *Mol. Cell. Biol.* 17  
440 (1997) 4419-4433.

- 441 [22] M.W. Sark, D.F. Fischer, E. de Meijer, P. van de Putte, C. Backendorf, AP-1 and ets  
1 transcription factors regulate the expression of the human SPRR1A keratinocyte  
2  
3  
4  
5 443 terminal differentiation marker, *J. Biol. Chem.* 273 (1998) 24683-24692.  
6
- 7 444 [23] S.P. Reddy, H. Vuong, P. Adiseshaiah, Interplay between proximal and distal promoter  
8  
9  
10 445 elements is required for squamous differentiation marker induction in the bronchial  
11  
12 446 epithelium: role for ESE-1, Sp1, and AP-1 proteins, *J. Biol. Chem.* 278 (2003) 21378-  
13  
14 447 21387.  
15
- 16 448 [24] C.H. Lee, L.N. Marekov, S. Kim, J.S. Brahim, M.H. Park, P.M. Steinert, Small proline-  
17  
18  
19 449 rich protein 1 is the major component of the cell envelope of normal human oral  
20  
21  
22 450 keratinocytes, *FEBS Lett.* 477 (2000) 268-272.  
23
- 24 451 [25] L. Lorand, R.M. Graham, Transglutaminases: crosslinking enzymes with pleiotropic  
25  
26 452 functions, *Nat. Rev. Mol. Cell Biol.* 4 (2003) 140-156.  
27  
28
- 29 453 [26] A.Y. Ng, P. Waring, S. Ristevski, C. Wang, T. Wilson, M. Pritchard, P. Hertzog, I.  
30  
31 454 Kola, Inactivation of the transcription factor Elf3 in mice results in dysmorphogenesis  
32  
33  
34 455 and altered differentiation of intestinal epithelium, *Gastroenterology* 122 (2002) 1455-  
35  
36 456 1466.  
37
- 38 457 [27] A.S. Hopkin, W. Gordon, R.H. Klein, F. Espitia, K. Daily, M. Zeller, P. Baldi, B.  
39  
40  
41 458 Andersen, GRHL3/GET1 and trithorax group members collaborate to activate the  
42  
43  
44 459 epidermal progenitor differentiation program, *PLoS Genet.* 8 (2012) e1002829.  
45
- 46 460 [28] W.M. Gordon, M.D. Zeller, R.H. Klein, W.R. Swindell, H. Ho, F. Espetia, J.E.  
47  
48  
49 461 Gudjonsson, P.F. Baldi, B. Andersen, A GRHL3-regulated repair pathway suppresses  
50  
51 462 immune-mediated epidermal hyperplasia, *J. Clin. Invest.* 124 (2014) 5205-5218.  
52
- 53 463 [29] M. Bock, J. Hinley, C. Schmitt, T. Wahlicht, S. Kramer, J. Southgate, Identification of  
54  
55  
56 464 ELF3 as an early transcriptional regulator of human urothelium, *Dev. Biol.* 386 (2014)  
57  
58 465 321-330.  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- 466 [30] C. Vandewalle, F. Van Roy, G. Berx, The role of the ZEB family of transcription  
467 factors in development and disease, *Cell. Mol. Life Sci.* 66 (2009) 773-787.
- 468 [31] E. Bonnet, M. Tatari, A. Joshi, T. Michoel, K. Marchal, G. Berx, Y. Van de Peer,  
469 Module network inference from a cancer gene expression data set identifies microRNA  
470 regulated modules, *PLoS One* 5 (2010) e10162.
- 471 [32] J.M. Andreoli, S.I. Jang, E. Chung, C.M. Coticchia, P.M. Steinert, N.G. Markova, The  
472 expression of a novel, epithelium-specific ets transcription factor is restricted to the  
473 most differentiated layers in the epidermis, *Nucleic Acids Res.* 25 (1997) 4287-4295.
- 474 [33] M. Matsuki, F. Yamashita, A. Ishida-Yamamoto, K. Yamada, C. Kinoshita, S. Fushiki,  
475 E. Ueda, Y. Morishima, K. Tabata, H. Yasuno, M. Hashida, H. Iizuka, M. Ikawa, M.  
476 Okabe, G. Kondoh, T. Kinoshita, J. Takeda, K. Yamanishi, Defective stratum corneum  
477 and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte  
478 transglutaminase), *Proc. Natl. Acad. Sci. U. S. A.* 95 (1998) 1044-1049.
- 479 [34] A. Mirza, S.L. Liu, E. Frizell, J. Zhu, S. Maddukuri, J. Martinez, P. Davies, R.  
480 Schwarting, P. Norton, M.A. Zern, A role for tissue transglutaminase in hepatic injury  
481 and fibrogenesis, and its regulation by NF-kappaB, *Am. J. Physiol.* 272 (1997) G281-  
482 288.
- 483 [35] L. Ai, R.R. Skehan, J. Saydi, T. Lin, K.D. Brown, Ataxia-Telangiectasia, Mutated  
484 (ATM)/Nuclear Factor kappa light chain enhancer of activated B cells (NFkappaB)  
485 signaling controls basal and DNA damage-induced transglutaminase 2 expression, *J.*  
486 *Biol. Chem.* 287 (2012) 18330-18341.
- 487 [36] N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, A. Sivachenko, G.V.  
488 Kryukov, M.S. Lawrence, C. Sougnez, A. McKenna, E. Shefler, A.H. Ramos, P.  
489 Stojanov, S.L. Carter, D. Voet, M.L. Cortes, D. Auclair, M.F. Berger, G. Saksena, C.  
490 Guiducci, R.C. Onofrio, M. Parkin, M. Romkes, J.L. Weissfeld, R.R. Seethala, L.

491 Wang, C. Rangel-Escareno, J.C. Fernandez-Lopez, A. Hidalgo-Miranda, J. Melendez-  
1  
2 492 Zajgla, W. Winckler, K. Ardlie, S.B. Gabriel, M. Meyerson, E.S. Lander, G. Getz, T.R.  
3  
4 493 Golub, L.A. Garraway, J.R. Grandis, The mutational landscape of head and neck  
5  
6  
7 494 squamous cell carcinoma, Science 333 (2011) 1157-1160.  
8  
9  
10 495 [37] A.A. AbdulMajeed, A.J. Dalley, C.S. Farah, Loss of ELF3 immunoexpression is useful  
11  
12 496 for detecting oral squamous cell carcinoma but not for distinguishing between grades of  
13  
14 497 epithelial dysplasia, Ann Diagn Pathol 17 (2013) 331-340.  
15  
16

17 498  
18  
19 499  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

500 **Figure Legends**

501 **Fig. 1. RIPK4 and IRF6 dependent regulation of ELF3 gene expression in human**

502 **keratinocytes.** (A-D) OKF6 cells were transfected with a (A-B) RIPK4 or (C-D) IRF6 siRNA  
503 (+), or control siRNA (-). (A) RIPK4 and (C) IRF6 mRNA levels in cells transfected with the  
504 control siRNA were each given an arbitrary value of 100% ( $n = 3$ ). (B and D) The cells were  
505 subsequently stimulated with PMA for 6 h, and ELF3 mRNA levels measured ( $n = 3$ ). (E-F)  
506 Human epidermal keratinocytes were transfected with a (E) RIPK4 or (F) IRF6 siRNA (+), or  
507 control siRNA (-). The cells were subsequently stimulated with PMA for 6 h, and ELF3  
508 mRNA levels measured ( $n = 3$ ). \*\*  $p < 0.01$ ; \*  $p < 0.05$ .

510 **Fig. 2. GRHL3 dependent regulation of ELF3 gene expression in human keratinocytes.**

511 (A-B) OKF6 cells were stimulated with PMA for the times indicated, and (A) ELF3 and (B)  
512 GRHL3 mRNA levels measured ( $n = 3$ ). (C) OKF6 cells were pretreated with actinomycin D  
513 (ActD) for 30 min, stimulated with PMA for 6 h, and ELF3 mRNA levels measured ( $n = 4$ ).  
514 (D-F) OKF6 cells were transfected with a GRHL3 (+) or control (-) siRNA. The cells were  
515 subsequently stimulated with PMA for 24 h (D and E) or 2 h (F), and (D) ELF3, (E) IVL, and  
516 (F) OVOL1 mRNA levels measured ( $n = 3$ ). \*\*  $p < 0.01$ ; \*  $p < 0.05$ .

518 **Fig. 3. Inhibition of protein synthesis results in increased ELF3 gene expression in**

519 **human keratinocytes.** OKF6 cells were pretreated with cycloheximide (CHX) and/or  
520 actinomycin D (ActD) for 30 min, stimulated with PMA for 6 h, and (A) ELF3, (B) IRF6, (C)  
521 GRHL3, and (D) RIPK4 mRNA levels measured by qPCR ( $n = 5$ ). \*\*  $p < 0.01$ ; \*  $p < 0.05$ .

523 **Fig. 4. RIPK4 and IRF6 dependent regulation of SPRR1 gene expression in human**

524 **keratinocytes.** (A-B and E-H) OKF6 cells and (C-D) normal human epidermal keratinocytes

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

525 were transfected with a (A-D) RIPK4, (E-F) IRF6, or (G-H) GRHL3 siRNA (+), or a control  
526 siRNA (-). The cells were subsequently stimulated with PMA for 24 h, and (A, C, E, and G)  
527 SPRR1A and (B, D, F, and H) SPRR1B mRNA levels measured ( $n = 4$ ). (I-J) OKF6 cells  
528 were pretreated with cycloheximide (CHX) for 30 min, stimulated with PMA for 6 h, and (I)  
529 SPRR1A and (J) SPRR1B mRNA levels measured ( $n = 4$ ). \*\* $p < 0.01$ ; \* $p < 0.05$ .

530  
531 **Fig. 5. RIPK4 and IRF6 dependent regulation of TGM1 gene expression in human**  
532 **keratinocytes.** (A, C, and D) OKF6 cells and (B) normal human epidermal keratinocytes  
533 were transfected with a (A-B) RIPK4, (C) IRF6, or (D) GRHL3 siRNA (+), or a control  
534 siRNA (-). The cells were subsequently stimulated with PMA for 24 h, and TGM1 mRNA  
535 levels measured ( $n = 3-5$ ). (E) OKF6 cells were pretreated with cycloheximide (CHX) for 30  
536 min, stimulated with PMA for 6 h, and TGM1 mRNA levels measured ( $n = 5$ ). \*\* $p < 0.01$ ; \*  
537  $p < 0.05$ .

538  
539 **Fig. 6. RIPK4 dependent regulation of TGM2 gene expression in human keratinocytes.**  
540 (A-C) OKF6 cells were transfected with a (A) RIPK4, (B) IRF6, or (C) GRHL3 siRNA (+),  
541 or a control siRNA (-). The cells were subsequently stimulated with PMA for 24 h, and  
542 TGM2 mRNA levels measured ( $n = 3$ ). (D) OKF6 cells were pretreated with cycloheximide  
543 (CHX) for 30 min, stimulated with PMA for 6 h, and TGM2 mRNA levels measured ( $n = 5$ ).  
544 \*\* $p < 0.01$ .

545  
546 **Fig. 7. A proposed model for the regulation of ELF3 gene expression in human**  
547 **keratinocytes by RIPK4.** The activation (phosphorylation) of IRF6 by RIPK4 promotes the  
548 expression of GRHL3, which induces, either directly or indirectly, ELF3 gene expression,  
549 culminating in the upregulation of SPRR1 gene expression. The upregulation of GRHL3



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

550 expression by RIPK4 and IRF6 concomitantly promotes the expression of TGM1, an enzyme  
551 that catalyses the cross-linking of small proline-rich proteins (e.g. SPRR1) to other structural  
552 proteins to facilitate the formation of the cornified envelope of terminally differentiated  
553 keratinocytes. RIPK4 also regulates, independently of IRF6 and GRHL3, the expression of  
554 TGM2.

Figure 1




Figure 2

[Click here to download high resolution image](#)

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7







Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Scholz, GM; Sulaiman, NS; Al Baiiaty, S; Kwa, MQ; Reynolds, EC

**Title:**

A novel regulatory relationship between RIPK4 and ELF3 in keratinocytes

**Date:**

2016-12-01

**Citation:**

Scholz, G. M., Sulaiman, N. S., Al Baiiaty, S., Kwa, M. Q. & Reynolds, E. C. (2016). A novel regulatory relationship between RIPK4 and ELF3 in keratinocytes. CELLULAR SIGNALLING, 28 (12), pp.1916-1922. <https://doi.org/10.1016/j.cellsig.2016.09.006>.

**Persistent Link:**

<http://hdl.handle.net/11343/123327>

**File Description:**

Accepted version